Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (452)	12/16/1999 1:37:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

I've been looking around for some stocks that haven't participated yet in the current gene-frenzy. One interesting possibility is GZMO. I think this is currently a little battered by tax-selling by investors that got the stock from GENZ. Most attention recently has been on their anti-angiogenic stuff, but we shouldn't forget that they are also a gene play: First Complete Human Transcriptome Described 12/10/99 SAGE (serial analysis of gene expression) has allowed researchers at Johns Hopkins University (Baltimore) to analyze a whopping 3.5 million transcripts from 19 normal and disease tissue types. As described in December's Nature Genetics, 46% of the transcripts identified represent new genes not present in existing databases. This work used a combination of public and private transcript databases, created by Genzyme Molecular Oncology (Framingham, MA). Full article at: bioresearchonline.com{81657083-AE5C-11D3-9A76-00A0C9C83AFB}&Bucket=R%26D+News I added a little more today. (I also own GZTC, which has a joint venture with them on aaATIII, and is itself a decent play on the also current mAb frenzy) Peter